back to US directory
us clinical guidance

Progestin-only pills

CDC method-specific eligibility, initiation, missed-pill instructions and follow-up for US progestin-only oral contraception.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Patients choosing an oral progestin-only contraceptive, including those who cannot or prefer not to use estrogen. US norethindrone, norgestrel and drospirenone pills have different schedules and missed-pill rules; this overview does not merge their product-specific instructions.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

The Bottom Line

  • Use U.S. MEC to assess medical conditions, but progestin-only pills are suitable for many patients whose estrogen-related thrombotic or cardiovascular risk precludes combined hormonal contraception.
  • A progestin-only pill may usually be started whenever the clinician is reasonably certain the patient is not pregnant; required backup depends on formulation and timing.
  • Norethindrone or norgestrel pills have a substantially shorter late-pill window than drospirenone pills, so counseling must identify the exact active ingredient rather than treating all minipills alike.
  • Irregular, frequent or absent bleeding can occur and is not by itself evidence of harm, but a new problematic pattern still warrants assessment for pregnancy, infection, medication effects or uterine disease when indicated.
  • Drospirenone has antimineralocorticoid activity, so kidney, adrenal and liver disease and medicines that increase potassium require product-specific eligibility and monitoring review.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Practical clinical workflow

1
Confirm the desired oral method, pregnancy possibility, postpartum and breastfeeding context, bleeding priorities, adherence routine, medical history and current prescriptions or supplements.
2
Apply the U.S. MEC category for breast cancer, liver disease, cardiovascular disease and other relevant conditions, then check formulation-specific FDA contraindications and interactions.
3
Dispense or prescribe the chosen formulation with a clear start date, backup duration and a written explanation of its own late or missed-pill algorithm.
4
Discuss what to do after vomiting or severe diarrhea, how to obtain emergency contraception after unprotected intercourse and when to resume pills without compounding missed doses.
5
At follow-up, review adherence, bleeding, pregnancy concerns, interactions and satisfaction, offering a different method promptly if the dosing demands do not fit the patient’s life.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Safety boundaries and escalation

  • A positive pregnancy test with pelvic pain, shoulder pain, dizziness or bleeding requires urgent assessment for ectopic pregnancy; pill use must not delay evaluation.
  • Current breast cancer is a major eligibility concern for hormonal contraception and requires specialist-aligned nonhormonal counseling rather than routine initiation.
  • Symptoms of clinically important hyperkalemia or a new potassium-raising medicine in a drospirenone user require prompt medication and laboratory review according to the current label.
  • Progestin-only pills do not prevent sexually transmitted infection; offer condoms and exposure-based testing rather than implying contraceptive efficacy equals infection protection.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Localization

This US page deliberately uses “progestin” and distinguishes locally marketed norethindrone, norgestrel and drospirenone pills. Availability, over-the-counter access, coverage and prescribing rules vary.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionU.S. Medical Eligibility Criteria for Contraceptive Use, 2024MMWR 2024;73(No. RR-4); DOI 10.15585/mmwr.rr7304a1 · published 2024-08-08 · accessed 2026-08-20
    view source
  2. Centers for Disease Control and PreventionU.S. Selected Practice Recommendations for Contraceptive Use, 2024MMWR 2024;73(No. RR-3); DOI 10.15585/mmwr.rr7303a1 · published 2024-08-08 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.